ALK-positive non–small cell lung cancer: Mechanisms of resistance and emerging treatment options

Author： Steuer Conor E.   Ramalingam Suresh S.  

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|120|16|2392-2402

ISSN： 0008-543X

Source： Cancer, Vol.120, Iss.16, 2014-08, pp. : 2392-2402

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies

By  

Current Clinical Pharmacology, Vol. 11, Iss. 2, 2016-08 ,pp. : 77-87

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging drugs for non-small cell lung cancer

By Cappuzzo Federico   Bartolini Stefania   Crinò Lucio  

Expert Opinion on Emerging Drugs, Vol. 8, Iss. 1, 2003-05 ,pp. : 179-192

Informa Healthcare

Access to resources Recommend Favorite

Management of Patients with Advanced Non-Small Cell Lung Cancer: Current and Emerging Options

By Triano Laura R.   Deshpande Hari   Gettinger Scott N.  

Drugs, Vol. 70, Iss. 2, 2010-01 ,pp. : 167-179

Adis International

Access to resources Recommend Favorite

Pemetrexed for the treatment of non-small cell lung cancer

By Genova Carlo  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 11, 2013-08 ,pp. : 1545-1558

Informa Healthcare

Access to resources Recommend Favorite

Vinorelbine in the Treatment of Non-Small Cell Lung Cancer

By  

Current Medicinal Chemistry, Vol. 9, Iss. 8, 2002-04 ,pp. : 879-891

Bentham Science Publishers

Access to resources Recommend Favorite